Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicine with non-small cell lung cancer resisting effect and use thereof

A non-small cell lung cancer, drug technology, applied in the direction of antineoplastic drugs, drug combinations, medical preparations containing active ingredients, etc., can solve the problems of drug resistance side effects, death, treatment can not continue, etc., to achieve strong anti-proliferation activity Effect

Active Publication Date: 2019-11-29
CHENZHOU NO 1 PEOPLES HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Tumor chemotherapy generally suffers from relatively large side effects, because it not only kills tumor cells, but also has a strong killing effect on normal cells. Many cancer patients cannot tolerate large doses of chemotherapy, resulting in the inability to continue treatment and death.
Although the targeted drug gefitinib has a certain therapeutic effect on some patients with EGFR mutations, and has achieved significant clinical curative effect, but after several courses of treatment, it will also produce certain drug resistance and side effects. Generally, recurrence or metastasis will occur within 1 to 2 years, or new mutations will be generated to produce resistance to gefitinib. Therefore, even treatment with gefitinib (tyrosine kinase inhibitor) still cannot effectively improve the Five-year overall survival in patients with non-small cell lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine with non-small cell lung cancer resisting effect and use thereof
  • Medicine with non-small cell lung cancer resisting effect and use thereof
  • Medicine with non-small cell lung cancer resisting effect and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1: NCI-H1975 (EGFR L858R / T790M ), HCC827 (EGFR E746-A750del ) and A549 (EGFR WT ) cell screening to optimize gefitinib Gef and febuxostat FBS composition

[0020] Take the cells in the logarithmic growth phase and inoculate 3×10 4 Cells / well were placed on a 96-well plate. After 6 hours of growth, the supernatant was discarded by centrifugation, and then administered according to the following groups: Tumor cells were divided into no drug group and drug-added group, and the drug-added group consisted of Gef and FBS single drugs Group, Gef and FBS combined drug groups with different molar ratios, set 4-6 duplicate wells in each group, culture for 24 hours, discard the supernatant, add 100 μl of MTT (tetrazolium salt) serum-free culture medium containing 0.5 mg / ml for culture After 4 hours, add 100 μl of DMSO (dimethyl sulfoxide), place on a micro-oscillator to vibrate for 10 minutes, and then place on a microplate reader to detect the OD value at 570 nm. R...

Embodiment 2

[0026] Embodiment 2: Expression of EGFR and Western blot detection

[0027] Immune Western blot antibodies were purchased from Abcam's C-Caspase-3 and anti-EGFR (ab52894) (Abcam). After the three kinds of cells were treated with gefitinib Gef or febuxostat FBS for 48 hours, 5×10 6 Cells were lysed with 200 μl of RIPA (50 mM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodiumdeoxycholate, 1% NP-40) and added protease inhibitors on ice for 30 minutes, then centrifuged at 12,000 rpm for 10 minutes, and the supernatant was collected for BCA method To measure protein concentration, add 2×SDS loading buffer and cook at 100°C for 10 minutes. The total protein (100 μg) was loaded, followed by 8-15% SDS-PAGE gel electrophoresis according to the molecular weight of the protein, and then transferred to a PVDF membrane (GE healthcare), incubated with corresponding antibodies, and the chemiluminescent enzyme substrate HRP Substrate ( Millipore Corporation), applied LAS-4000 imaging system im...

Embodiment 3

[0028] Example 3: FBS drug inhibits tumor growth in non-small cell lung cancer tumor-bearing mice

[0029] In order to test the efficacy of FBS on non-small cell lung cancer in vivo, we established a mouse tumor model of non-small cell lung cancer in nude mice using NCI-H1975 cells. Including control group (Control) (physiological saline); FBS (300mg / kg / d, intragastric administration) and Gef (25mg / kg / d, intragastric administration) groups and the Gef / FBS combination group with the same dose as single use, each group 10 nude mice, after subcutaneous inoculation of tumors, when the subcutaneous tumor volume is greater than 100mm 3 At that time, the mice were randomly divided into four groups, and intragastric administration was started after the 7th day, once a day, and the body weight change and tumor volume were weighed the next day, and the suspension was diluted with normal saline. The major diameter and minor diameter of the tumor were measured with a vernier caliper ever...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine treatment, and discloses a medicine with non-small cell lung cancer resisting effect and use thereof. The active ingredient of the medicine is febuxostat. The invention firstly proposes a method for treating non-small cell lung cancer with febuxostat and its application in preparing a medicine for treating non-small cell lung cancer, the use of febuxostat in the treatment of non-small cell lung cancer is a promising clinical strategy of conventional drug in new use, which is benefit more patients with non-small cell lung cancer.

Description

technical field [0001] The invention belongs to the field of drug therapy, in particular to a drug with anti-non-small cell lung cancer effect and its application. Background technique [0002] Cancer is a major chronic disease that seriously endangers human health, and has become the second largest killer after cardiovascular disease. Lung cancer is the first malignant tumor with the highest morbidity and mortality, and non-small cell lung cancer (NSCLC for short) accounts for 80% of lung cancer. Currently, chemotherapy is still the main treatment for NSCLC. For the presence of EGFR L858R Patients with mutations or different deletion mutations in exon 19 of EGFR (common in Asians, females, non-smoking patients, and non-small cell lung cancer patients) have a better effect of targeted therapy with gefitinib (Gef; also known as Iressa). [0003] Tumor chemotherapy generally suffers from relatively large side effects, because it kills tumor cells and also has a strong killi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/426A61P35/00
CPCA61K31/426A61P35/00
Inventor 陈美姿周融融胡洪波彭咏波
Owner CHENZHOU NO 1 PEOPLES HOSPITAL